On 26 April 2026, the European Commission notified WTO/TBT G/TBT/N/EU/1128 — a draft amendment to EN 1822-1:2026 mandating microbial viability reduction (MVR) testing for industrial-grade ULPA filters used in pharmaceutical production, biolabs, and cleanrooms. This development directly affects manufacturers and exporters supplying these high-containment environments.

Event Overview

The European Commission issued draft regulation G/TBT/N/EU/1128 on 26 April 2026 via the WTO/TBT notification system. It proposes amending EN 1822-1:2026 to require mandatory microbial viability reduction (MVR) verification for ULPA filters deployed in pharmaceutical, biotechnology laboratory, and cleanroom industrial applications. The test must follow ISO 29463-3:2026 Annex F using Bacillus atrophaeus, with a minimum log₁₀ reduction of 6.5. The regulation is scheduled to enter into force in Q1 2027. Exporters from China — and other third countries — will be required to obtain third-party MVR test reports and update their CE technical documentation accordingly.

Industries Affected by This Regulation

Direct Exporters to the EU

Manufacturers exporting ULPA filters to the EU for regulated end-use (e.g., sterile drug manufacturing or Class A cleanrooms) will face new conformity assessment requirements. Compliance is no longer based solely on particle filtration efficiency (e.g., EN 1822’s E12–U17 classification), but now includes biological performance validation. Non-compliant products may be rejected at EU borders or withdrawn post-market.

Filter Module & System Integrators

Companies assembling ULPA filter modules into HVAC systems or isolators for pharma clients must verify that individual filter elements meet the MVR requirement. Since MVR is a filter-media-level property, integrators cannot rely on system-level testing alone — component-level third-party MVR certification becomes essential for CE marking of the full system.

Raw Material & Media Suppliers

Suppliers of ULPA-grade filter media (e.g., ultrafine glass fiber or electrospun polymer membranes) may see increased demand for pre-validated materials. While the draft does not impose direct obligations on upstream suppliers, downstream filter manufacturers are likely to request MVR performance data or co-certification to streamline their own compliance timelines.

Testing & Certification Service Providers

Laboratories accredited to ISO/IEC 17025 and capable of performing ISO 29463-3:2026 Annex F testing will experience rising demand for MVR verification. As this is a newly mandated test under CE, capacity constraints and lead times for reporting may emerge — particularly for labs outside the EU lacking prior experience with B. atrophaeus-based viability assays.

What Enterprises and Practitioners Should Focus On Now

Monitor Official Updates Through the EU’s TBT Enquiry Point

The draft remains subject to WTO comment periods and possible revision before adoption. Stakeholders should track official updates via the EU’s TBT Enquiry Point (https://ec.europa.eu/growth/tools-databases/tbt/) and national enquiry points — especially any clarifications on scope (e.g., whether retroactive application applies to existing certified filters) or transitional arrangements.

Identify Which Filter SKUs Fall Under the Mandatory Scope

Not all ULPA filters are covered: only those intended for pharmaceutical, biolab, or cleanroom industrial use as defined in the draft’s scope. Companies should review product labeling, marketing claims, and technical documentation to determine whether their filters are explicitly positioned for these high-risk applications — as that triggers the MVR obligation, regardless of physical filter class.

Distinguish Between Policy Signal and Operational Requirement

While the draft signals a clear regulatory direction, formal adoption and transposition into national law are pending. Current CE declarations remain valid until Q1 2027 — but preparing MVR reports ahead of time avoids last-minute bottlenecks. Importantly, MVR is not a substitute for existing EN 1822 efficiency and leak testing; it is an additional, parallel requirement.

Initiate Third-Party MVR Testing and Documentation Alignment

Exporters should engage accredited labs now to conduct pilot MVR tests on representative filter batches. Concurrently, revise technical files to include MVR methodology, raw data, uncertainty statements, and traceability to reference strains — aligning with the structure expected under the revised EN 1822-1:2026 annexes. Internal training for QA/QC teams on MVR interpretation is also advisable.

Editorial Perspective / Industry Observation

This draft is best understood as a signal — not yet an outcome — of the EU’s evolving risk-based approach to air filtration in critical life-science infrastructure. Analysis来看, the inclusion of MVR reflects growing regulatory attention to biological integrity beyond particulate control, particularly following recent incidents involving microbial contamination in aseptic processing. From industry perspective, it marks a shift from ‘filtering particles’ to ‘controlling viable pathogens’ as a core CE requirement. Observation来看, the timing — aligned with ISO 29463-3:2026’s publication — suggests coordinated standardization rather than ad hoc intervention. However, its practical impact hinges on enforcement clarity: whether Notified Bodies will treat MVR as a standalone module or integrate it into broader quality management audits remains to be seen.

Conclusion

This draft represents a targeted, technically specific evolution in EU air filtration regulation — not a broad sectoral overhaul. Its significance lies in introducing biological performance as a mandatory CE criterion for a defined subset of ULPA filters. For affected stakeholders, the current phase is preparatory: verifying applicability, initiating testing readiness, and monitoring procedural details. It is more accurately interpreted as the start of a 12-month alignment window than an immediate compliance deadline.

Information Sources

Main source: WTO/TBT Notification G/TBT/N/EU/1128, published 26 April 2026. The status and final text of the amended EN 1822-1 standard remain subject to ongoing standardization processes within CEN/TC 195 and subsequent EU Commission adoption. These developments require continued observation.